US OTC Monograph Facilty Fees Increase With Pandemic-Inspired Sanitizer Makers Exempted
Executive Summary
FDA publishes second notice on FY2021 rates for OTC monograph drug user fee program. With fewer firms paying, those still subject to facility fees will pay more so the total collected matches amount Congress authorized agency to collect, nearly $23.3m.
You may also be interested in...
US FDA Asks For Comments On Reauthorizing OMUFA, A Program Still New To OTC Industry
Agency conducting all-day online meeting on 28 September to discuss proposed first reauthorization of OMUFA program established with its first five-year authorization in 2020 in legislation to overhaul the OTC monograph program.
US OTC Monograph Overhaul Meets DFO Deadline As Stakeholders Make User Fee Introductions
Last of 32 OTC monographs finalized as required in 2020 reform legislation as some stakeholders ask if the agency is collecting user fees yet.
End Is Near For Distributing OTC Hand Sanitizers Manufactured Under Temporary US Guidance
The 31 March cut-off date brings to a comparatively low-profile end a well-chronicled saga of FDA acting to increase OTC hand sanitizer production as consumer demand soared in response to COVID-19.